Illumina, pioneer Broad Institute to work on new gene sequencing kits
Aug 13 (Reuters) -Illumina ILMN.O said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene sequencing using a novel method based on the Nobel Prize-winning CRISPR technology.
In a separate partnership with Broad Institute and Harvard, San Diego-based Illumina will work on research sequencing of single cells and conduct experiments using technology from the company's recently acquired Fluent BioSciences.
WHY IT'S IMPORTANT
Illumina's partnership with Massachusetts-based Broad Institute - one of the most prominent names in CRISPR research - aims to use a new method called PerturbSeq screening for scaling up gene sequencing volume.
This could help in disease and treatment research, as well as drive Illumina's growth.
KEY QUOTE
"PerturbSeq has already demonstrated it can significantly advance the understanding of healthy gene networks and what goes wrong in the context of (a) disease. We believe it will set the scene for the next revolution in biology," said Illumina CEO Jacob Thaysen during a presentation.
CONTEXT
The gene sequencing industry has seen significant developments in the last decade, especially the discovery of CRISPR, a part of DNA found in bacteria's immune system, which is now used in genetic editing.
Illumina expects the partnerships for the new technologies to give the company the boost it needs. It has been struggling with the lack of revenue growth due to weakness in biotech funding.
BY THE NUMBERS
The company expects the partnership to help it achieve a double-digit percentage growth in its adjusted profit between 2025 and 2027, and high-single digit rise in revenue by 2027.
In 2023, the company's revenue declined 2% to $4.50 billion, while its adjusted profit fell to 86 cents per share from $2.12.
Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
